Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Licensing > BDA202202

CD47 Monoclonal Antibody

Discovery
Preclinical
IND
PH1
PH2
PH3
BLA Filing
Active
  • Project profile
    Project name: CD47 Monoclonal Antibody
    Indications: Hematologic tumors, solid tumors
    Research phase: License-out or co-development
    Cooperation demands: License-out or co-development
  • Highlights

    1. Binds to human CD47 on a novel epitope.


    2. Better neutralization ability and anti-tumor efficacy than Hu5F9.



    Better neutralization ability and anti-tumor efficacy than Hu5F9


    3. Shows great potential in combination with anti-PD-1 therapies .



    Shows great potential in combination with anti-PD-1 therapies


    4. Low erythrocyte binding and cause no hemagglutination in vitro.


    5. In acute and chronic GLP toxicity studies in cynomolgus monkeys, DS003 did not cause anaemia or thrombopenia.


    In acute and chronic GLP toxicity studies in cynomolgus monkeys, DS003 did not cause anaemia or thrombopenia.

  • Project Introduction

    1. Asset type: Humanized recombinant CD47 Monoclonal Antibody

    2. Indication: Hematologic tumors, solid tumors

    3. Research phase: IND approval is expected

    4. Cooperation demands: License-out or co-development

    5. Research progress:
    1) Erythrocyte binding and hemagglutination assay was completed. The asset showed low erythrocyte binding and did not cause hemagglutination of human erythrocytes in vitro.
    2) Monkey single/ multiple dose toxicity studies were completed. The asset did not cause anaemia or thrombopenia.
    3) The stable cell line of the asset has been established in CHO host cells with commercial license.
    4) IND approval is expected in the 3rd quarter of 2022.

Comments (0)

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message